Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/II, First in Human, Single Arm, Open Label Study to Evaluate the Safety and Efficacy of the Injection of Triple-specific T-cell Engager 1A46in Adult Subjects with R/R CD20 Positive And/or CD19 Positive B Cell Non-Hodgkin's Lymphoma (B - NHL)

NCT05987605 is registered in ClinicalTrials.gov with BioRay Pharmaceutical Co., Ltd. as lead sponsor.

NCT NCT05987605
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05987605 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/II, First in Human, Single Arm, Open Label Study to Evaluate the Safety and Efficacy of the Injection of Triple-specific T-cell Engager 1A46in Adult Subjects with R/R CD20 Positive And/or CD19 Positive B Cell Non-Hodgkin's Lymphoma (B - NHL)
Lead sponsor
BioRay Pharmaceutical Co., Ltd.
Phase
Phase 1
Overall status
Terminated
Start date
September 12, 2023
Completion date
November 1, 2024
Enrollment
4 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

advanced malignancies